Cargando…
A review of the genome, epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspects
BACKGROUND: The ongoing acute respiratory disease pandemic termed COVID-19 caused by a newly emerged coronavirus has jeopardized the world’s health and economic sectors. As of 20 July 2020, the virus now known as SARS-CoV-2 has already infected more than 14 million individuals and killed 612,815 pat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844806/ http://dx.doi.org/10.1186/s43168-021-00053-2 |
_version_ | 1783644427378491392 |
---|---|
author | Al Noman, Abdullah Islam, Md. Shofiqul Sana, Samiron Mondal, Prapti Meem, Rima Islam Rana, Sohel Mondol, Debashish Sana, Manoshi Hossain, Sheikh I. Joarder, Taufique Mazumder, Kishor |
author_facet | Al Noman, Abdullah Islam, Md. Shofiqul Sana, Samiron Mondal, Prapti Meem, Rima Islam Rana, Sohel Mondol, Debashish Sana, Manoshi Hossain, Sheikh I. Joarder, Taufique Mazumder, Kishor |
author_sort | Al Noman, Abdullah |
collection | PubMed |
description | BACKGROUND: The ongoing acute respiratory disease pandemic termed COVID-19 caused by a newly emerged coronavirus has jeopardized the world’s health and economic sectors. As of 20 July 2020, the virus now known as SARS-CoV-2 has already infected more than 14 million individuals and killed 612,815 patients with a mortality rate of 4.12% around the world regardless of age, gender, and race. MAIN BODY: Bangladesh has become one of its worst sufferers, with 207,453 infected people and 2668 related deaths with a mortality rate of 1.29% until 20 July 2020. More than 50% of COVID-19 patients in Bangladesh are aged between 21 and 40, but elderly people aged more than 60 have the highest mortality rate (44.7%). Male individuals are also more susceptible to the virus than females and consist of 71% and 79% among the infected and deceased patients, respectively. The most prevalent clinical features following the virus incubation period are fever, fatigue, and dry cough. A phylogenetic analysis study elucidated that the virus strain found in the country has 9 single-nucleotide variants, mostly in the ORF1ab gene, and a sequence containing 3 successive variants in the N protein, which reflects a weaker strain of SARS-CoV-2, implicating a possibility of its lower mortality rate. Another investigation of 184 genome samples of SARS-CoV-2 across the country implicated a close homology with a European haplotype of SARS-CoV-2. The country has also joined the race of vaccine development and started phase III clinical trials of a candidate vaccine developed by Sinovac Research and Development Co Ltd, China. CONCLUSION: Bangladesh, as a developing country, still struggles with the pandemic and needs to scale up its response operation and improve healthcare facilities such as testing capacity, institutional quarantine, and isolation centers and promote awareness. Preventive measures such as strict lockdown, social distancing, and boosting the existing immune system are thus considered the only contrivances. |
format | Online Article Text |
id | pubmed-7844806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-78448062021-01-29 A review of the genome, epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspects Al Noman, Abdullah Islam, Md. Shofiqul Sana, Samiron Mondal, Prapti Meem, Rima Islam Rana, Sohel Mondol, Debashish Sana, Manoshi Hossain, Sheikh I. Joarder, Taufique Mazumder, Kishor Egypt J Bronchol Reviews BACKGROUND: The ongoing acute respiratory disease pandemic termed COVID-19 caused by a newly emerged coronavirus has jeopardized the world’s health and economic sectors. As of 20 July 2020, the virus now known as SARS-CoV-2 has already infected more than 14 million individuals and killed 612,815 patients with a mortality rate of 4.12% around the world regardless of age, gender, and race. MAIN BODY: Bangladesh has become one of its worst sufferers, with 207,453 infected people and 2668 related deaths with a mortality rate of 1.29% until 20 July 2020. More than 50% of COVID-19 patients in Bangladesh are aged between 21 and 40, but elderly people aged more than 60 have the highest mortality rate (44.7%). Male individuals are also more susceptible to the virus than females and consist of 71% and 79% among the infected and deceased patients, respectively. The most prevalent clinical features following the virus incubation period are fever, fatigue, and dry cough. A phylogenetic analysis study elucidated that the virus strain found in the country has 9 single-nucleotide variants, mostly in the ORF1ab gene, and a sequence containing 3 successive variants in the N protein, which reflects a weaker strain of SARS-CoV-2, implicating a possibility of its lower mortality rate. Another investigation of 184 genome samples of SARS-CoV-2 across the country implicated a close homology with a European haplotype of SARS-CoV-2. The country has also joined the race of vaccine development and started phase III clinical trials of a candidate vaccine developed by Sinovac Research and Development Co Ltd, China. CONCLUSION: Bangladesh, as a developing country, still struggles with the pandemic and needs to scale up its response operation and improve healthcare facilities such as testing capacity, institutional quarantine, and isolation centers and promote awareness. Preventive measures such as strict lockdown, social distancing, and boosting the existing immune system are thus considered the only contrivances. Springer Berlin Heidelberg 2021-01-29 2021 /pmc/articles/PMC7844806/ http://dx.doi.org/10.1186/s43168-021-00053-2 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Reviews Al Noman, Abdullah Islam, Md. Shofiqul Sana, Samiron Mondal, Prapti Meem, Rima Islam Rana, Sohel Mondol, Debashish Sana, Manoshi Hossain, Sheikh I. Joarder, Taufique Mazumder, Kishor A review of the genome, epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspects |
title | A review of the genome, epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspects |
title_full | A review of the genome, epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspects |
title_fullStr | A review of the genome, epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspects |
title_full_unstemmed | A review of the genome, epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspects |
title_short | A review of the genome, epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspects |
title_sort | review of the genome, epidemiology, clinical features, prevention, and treatment scenario of covid-19: bangladesh aspects |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844806/ http://dx.doi.org/10.1186/s43168-021-00053-2 |
work_keys_str_mv | AT alnomanabdullah areviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT islammdshofiqul areviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT sanasamiron areviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT mondalprapti areviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT meemrimaislam areviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT ranasohel areviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT mondoldebashish areviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT sanamanoshi areviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT hossainsheikhi areviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT joardertaufique areviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT mazumderkishor areviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT alnomanabdullah reviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT islammdshofiqul reviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT sanasamiron reviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT mondalprapti reviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT meemrimaislam reviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT ranasohel reviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT mondoldebashish reviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT sanamanoshi reviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT hossainsheikhi reviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT joardertaufique reviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects AT mazumderkishor reviewofthegenomeepidemiologyclinicalfeaturespreventionandtreatmentscenarioofcovid19bangladeshaspects |